Viridian Therapeutics, Inc.\DE (VRDN) Total Non-Current Liabilities (2014 - 2026)
Viridian Therapeutics, Inc.\DE (VRDN) posted quarterly Total Non-Current Liabilities of $140.5 million for Q1 2026, up 157.23% year-over-year from $54.6 million in Q1 2025, and down 10.63% quarter-over-quarter from $157.2 million in Q4 2025.
Viridian Therapeutics, Inc.\DE (VRDN) Total Non-Current Liabilities (2014 - 2026) Analysis & Trends
Viridian Therapeutics, Inc.\DE's Total Non-Current Liabilities history runs 13 years deep, the most recent figure standing at $140.5 million for Q1 2026.
- In Q1 2026, Total Non-Current Liabilities rose 157.23% year-over-year to $140.5 million; the TTM figure through Mar 2026 stood at $140.5 million (up 157.23% YoY), while the FY2025 annual figure was $157.2 million, up 129.67% from the prior year.
- Total Non-Current Liabilities for Q1 2026 stood at $140.5 million, down from $157.2 million in the prior quarter.
- The five-year high for Total Non-Current Liabilities was $157.2 million in Q4 2025, with the low at $15.5 million in Q1 2022.
- The 5-year median for Total Non-Current Liabilities is $47.4 million (2023), against an average of $58.5 million.
- Peak annual rise in Total Non-Current Liabilities reached 162.8% in 2022, while the deepest fall reached 7.96% in 2022.
- Viridian Therapeutics, Inc.\DE's Total Non-Current Liabilities stood at $38.9 million in 2022, then gained by 22.03% to $47.4 million in 2023, then surged by 44.38% to $68.5 million in 2024, then jumped by 129.67% to $157.2 million in 2025, then dropped by 10.63% to $140.5 million in 2026.
- Business Quant data shows VRDN's Total Non-Current Liabilities at $140.5 million in Q1 2026, $157.2 million in Q4 2025, and $71.6 million in Q3 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Total Non-Current Liabilities (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 128.13 Bn | 120.28 Bn | 2.84 Bn | 5.92 Bn |
| 2 | Regeneron Pharmaceuticals | 112.33 Bn | 104.33 Bn | 3.93 Bn | 7.74 Bn |
| 3 | Argenx Se | 53.24 Bn | 48.05 Bn | 1.41 Bn | 40.00 Mn |
| 4 | Revolution Medicines | 43.64 Bn | 43.64 Bn | - | 1.53 Bn |
| 5 | BeOne Medicines | 39.27 Bn | 34.17 Bn | 1.53 Bn | 1.88 Bn |
| 6 | MindWalk Holdings | 35.32 Bn | 35.31 Bn | 1.82 Bn | - |
| 7 | Royalty Pharma | 33.72 Bn | 35.84 Bn | - | 9.32 Bn |
| 8 | Alnylam Pharmaceuticals | 30.58 Bn | 27.27 Bn | 992.69 Mn | 4.20 Bn |
| 9 | Insmed | 27.01 Bn | 25.85 Bn | 358.27 Mn | 1.17 Bn |
| 10 | Viridian Therapeutics, Inc.\DE | 2.50 Bn | 2.50 Bn | - | 421.45 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | 421.45 Mn |
| Mar 31, 2026 | 140.51 Mn |
| Dec 31, 2025 | 157.22 Mn |
| Sep 30, 2025 | 71.59 Mn |
| Jun 30, 2025 | 65.08 Mn |
| Mar 31, 2025 | 54.62 Mn |
| Dec 31, 2024 | 68.46 Mn |
| Sep 30, 2024 | 62.24 Mn |
| Jun 30, 2024 | 54.68 Mn |
| Mar 31, 2024 | 46.96 Mn |
| Dec 31, 2023 | 47.41 Mn |
| Sep 30, 2023 | 43.89 Mn |
| Jun 30, 2023 | 34.08 Mn |
| Mar 31, 2023 | 35.05 Mn |
| Dec 31, 2022 | 38.86 Mn |
| Sep 30, 2022 | 30.76 Mn |
| Jun 30, 2022 | 26.98 Mn |
| Mar 31, 2022 | 15.46 Mn |
| Dec 31, 2021 | 14.79 Mn |
| Sep 30, 2021 | 14.34 Mn |